share_log

Guggenheim Reiterates Buy on Blueprint Medicinesto Buy

Benzinga ·  Dec 12 00:58

Guggenheim analyst Michael Schmidt reiterates Blueprint Medicines (NASDAQ:BPMC) from Buy to Buy.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment